- Cassava stock increased 49% last Thursday as a short attack fell on deaf ears in favor of a positive report from the Journal of Neuroscience.
- The short thesis on simufilam may or may not have merit. The problem is shorts misunderstood market forces and are setting themselves up to be the victims of a squeeze.
- SAVA stock compares quite favorably to other meme stocks in terms of market cap, short interest and float. Short interest is 30% of the float as of 10/29.
- The top bonus threshold for management's cash incentive plan is achieved if SAVA holds $119 or more for 20 consecutive business days.
- Last week's spike in price combined with an active options market leaves SAVA stock as a prime candidate for a gamma squeeze.
For further details see:
Cassava Sciences Stock: Top Contender For A Continued Short Squeeze